Combined inhibition of BCL2 activity and CD28 signaling to prevent graft-versus-host disease

Post-transplantation cyclophosphamide (PTCy)-based prophylaxis has become one of the most widely used strategies to prevent graft-versus-host disease (GVHD), particularly after HLA-haploidentical hematopoietic cell transplantation (HCT). Well-tolerated GVHD prophylaxis regimens beyond PTCy are needed, because adverse events associated with Cy administration, such as cardiac toxicity, remain a safety concern. Costimulation blockade using abatacept (ABA) is an established complementary strategy to improve GVHD prevention without a calcineurin inhibitor. Here, we investigated venetoclax (VEN), a selective B-cell leukemia/lymphoma 2 (BCL-2) inhibitor, as a candidate partner with ABA to prevent GVHD. In a murine MHC-haploidentical HCT model, we demonstrate that prevention of GVHD with a combination of short-term VEN and CD28 costimulation blockade using ABA (VEN+ABA) was comparable to that with Cy+ABA and superior to that with Cy monotherapy, while maintaining GVL effects. Flow cytometry analysis revealed a higher regulatory T (Treg)/conventional T (Tcon) ratio with the VEN+ABA combination compared to Cy+ABA. Using donor CD8+ alloreactive TCR-transgenic T cells, we show that the VEN+ABA combination produced a prominent cleaved caspase-3 signature only in allo-activated T cells, and cells from the spleen at day 9 after HCT with VEN+ABA did not respond after ex vivo CD3/CD28 stimulation. Collectively, our study supports a VEN+ABA GVHD prophylaxis strategy associated with preferential apoptosis of alloreactive T cells while preserving GVL activity to replace alkylator-based prophylaxis.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2026-11-17
DOI
https://doi.org/10.1182/bloodadvances.2026021048
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Combined inhibition of BCL2 activity and CD28 signaling to prevent graft-versus-host disease

Megumi Narisawa, Atsushi Enomoto, Hiroyoshi Nishikawa, Akihiro Tomita et al.
Blood Advances
Hematopoietic Stem Cell Transplantation
article

Combined inhibition of BCL2 activity and CD28 signaling to prevent graft-versus-host disease

Megumi Narisawa, Atsushi Enomoto, Hiroyoshi Nishikawa, Akihiro Tomita, Yasuhiro Maeda, Sachiko Ito, Yoshiki Akatsuka, Yuki Miyai, Qiuyu Zhao, Carolyne Barakat, Hao Chen, Xin Lu
article en

Abstract

Post-transplantation cyclophosphamide (PTCy)-based prophylaxis has become one of the most widely used strategies to prevent graft-versus-host disease (GVHD), particularly after HLA-haploidentical hematopoietic cell transplantation (HCT). Well-tolerated GVHD prophylaxis regimens beyond PTCy are needed, because adverse events associated with Cy administration, such as cardiac toxicity, remain a safety concern. Costimulation blockade using abatacept (ABA) is an established complementary strategy to improve GVHD prevention without a calcineurin inhibitor. Here, we investigated venetoclax (VEN), a selective B-cell leukemia/lymphoma 2 (BCL-2) inhibitor, as a candidate partner with ABA to prevent GVHD. In a murine MHC-haploidentical HCT model, we demonstrate that prevention of GVHD with a combination of short-term VEN and CD28 costimulation blockade using ABA (VEN+ABA) was comparable to that with Cy+ABA and superior to that with Cy monotherapy, while maintaining GVL effects. Flow cytometry analysis revealed a higher regulatory T (Treg)/conventional T (Tcon) ratio with the VEN+ABA combination compared to Cy+ABA. Using donor CD8+ alloreactive TCR-transgenic T cells, we show that the VEN+ABA combination produced a prominent cleaved caspase-3 signature only in allo-activated T cells, and cells from the spleen at day 9 after HCT with VEN+ABA did not respond after ex vivo CD3/CD28 stimulation. Collectively, our study supports a VEN+ABA GVHD prophylaxis strategy associated with preferential apoptosis of alloreactive T cells while preserving GVL activity to replace alkylator-based prophylaxis.

Blood Advances
Fujita Health University (JP), Kyoto University (JP), National Cancer Centre Japan (JP), Nagoya University (JP)
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon